Insights from BCC Research

Laurie L. Sullivan

Recent Posts

Liquid Biopsy Market Soars Ever Higher

Posted by Laurie L. Sullivan on Oct 9, 2017 11:00:00 AM

Liquid biopsy is rapidly gaining traction as a supplement or alternative to tissue biopsy. Earlier this year, we noted that liquid biopsies continue to draw investments, and efforts prevail to establish the technique in mainstream medicine. Liquid biopsies have been likened to a Holy Grail of cancer treatment. By means of a simple blood draw, liquid biopsies aim to replace needle biopsies of solid tumors, which can be expensive for the healthcare system as well as painful for patients. For diagnosis of cancer, liquid biopsies could spare some of the risky tissue biopsies and reduce reliance on computed tomography scans, which must be limited because of the danger posed by overexposure to radiation.

Read More

Topics: Life Sciences, Pharmaceuticals

What Happens When Robotic Sensors and Bionics Meet?

Posted by Laurie L. Sullivan on Sep 26, 2017 10:00:00 AM

Bionics.pngThe answer: An augmented reality.

Read More

Topics: Instrumentation and Sensors

Liquid Biopsy Market Gets Off to Big Start in 2016

Posted by Laurie L. Sullivan on Sep 22, 2017 6:00:00 AM

UPDATED LIQUID BIOPSY BLOG

Liquid biopsies have been likened to a Holy Grail of cancer treatment. By means of a simple blood draw, liquid biopsies aim to replace needle biopsies of solid tumors, which can be expensive for the healthcare system as well as invasive and painful for patients. For diagnosis of cancer, liquid biopsies could spare some of the risky tissue biopsies and reduce reliance on CT scans, which must be limited because of the danger posed by overexposure to radiation.

Read More

As Demand Surges, Drug Tests Deliver on Speed and Simplicity

Posted by Laurie L. Sullivan on Sep 13, 2017 11:00:00 AM

fingerprint-Drug Testing.jpgThe steadily increasing demand for substance abuse test equipment forms a building block for medical technology companies, according to a new study by BCC Research. From estimated sales of $3 billion in 2016, the global drug testing industry is predicted to reach almost $4 billion by 2022. Technological advances and the entry of new innovative companies in the diagnostics industry have transformed the market.

Read More

Topics: Life Sciences, Pharmaceuticals